accutane
- Thread starter NAIR
- Start date
noel
New member
no, but i heard it works very very well, but my dermatologist said you have to stear clear of the sun or tanning and also be in good mental condition, i guess if you have had any previous issues w/ using meds. related to your mental state weather temp. or long term they probably woulndt give it too you. some patients have become suicidal, but others say thats just crap. thats all i know, oh and extreme dryness were applied and near, i am talking creacked lips and eyelids to the efeect of blistering. if your into comp. building and need your body to look its best you would probably have to not use this or take some time off, because they say usually after 6mnths of intense use your acne wont return. is yours adult acne or caused from you cycle ?
Accutane should be used as a last ditch effort to combat extremely bad cases of acne. For slight acne problems like so many of us get like my hubby daFonz I suggest you use benzoyl peroxide @ 2%.
Accutane can do much more harm than good when used to treat acne.
If you have acne from being on cycle try this: Vit B5 @ 5grams ED, benzoyl peroxide @ 2% (anything higher and it can overdry your skin), tanning, and EFA's.
Accutane can do much more harm than good when used to treat acne.
If you have acne from being on cycle try this: Vit B5 @ 5grams ED, benzoyl peroxide @ 2% (anything higher and it can overdry your skin), tanning, and EFA's.
well 10% is wayyyyyyyyyyyyy to much. There are med documents which show that 10% is not more effective and will in fact cause overdrying.
Trust me try a 2% from a simple comp like clean and clear and you'll find it will work better for you than the 10% you were using. More isnt better, also high % of benzoyl peroxide will bleach clothing if you get it on it.
Trust me try a 2% from a simple comp like clean and clear and you'll find it will work better for you than the 10% you were using. More isnt better, also high % of benzoyl peroxide will bleach clothing if you get it on it.
my girl started on accutane almost 2 weeks ago. 10mg/day.
she has bad acne genetically. Not much results wise yet, but the dose may be too low (rather start low than high). Ive only noticed her face isnt as red and inflammed, but that may because she stopped picking at it so much (which I told her to do a long time ago.)
she says her face feels a little dryer, so even at the low dose, results are starting.
she has bad acne genetically. Not much results wise yet, but the dose may be too low (rather start low than high). Ive only noticed her face isnt as red and inflammed, but that may because she stopped picking at it so much (which I told her to do a long time ago.)
she says her face feels a little dryer, so even at the low dose, results are starting.
Stickler*
Active member
FDA blurb on accutane:
iPLEDGE Update (10/6/2006): FDA is providing an update about iPLEDGE, a risk management program to reduce the risk of fetal exposure to isotretinoin (a drug to treat severe recalcitrant nodular acne). Today’s change will eliminate one element of the program, the 23 day lock-out period for males and females of non-child bearing potential (FNCBP). Previously, all patients prescribed isotretinoin had to fill their prescription within 7 days of their office visit. Patients who missed this window of opportunity and attempted to fill their prescription after 7 days had elapsed could not receive isotretinoin for another 23 days, a provision designed to prevent potential exposure to the drug during pregnancy. The elimination of the 23 day lock-out period for males and FNCBP will allow these patients the ability to have a new prescription filled immediately after the 7 day window has expired. This change does not affect female patients of child-bearing potential, and the iPLEDGE call center cannot authorize exceptions. Questions and Answers regarding iPLEDGE can be viewed at
FDA ALERT [11/2005]: Start Dates Have Been Changed for the iPLEDGE Program. FDA approved a strengthened risk management plan for Accutane and generic isotretinoin on August 12, 2005, to make sure females do not become pregnant while taking this medicine. Isotretinoin causes birth defects. This new plan is called iPLEDGE. The iPLEDGE program was originally scheduled to begin on November 1, 2005. To allow more time for registration and activation, the implementation dates of the iPLEDGE program have been revised. The start date by which wholesalers and pharmacies must be registered /activated in iPLEDGE has been changed from November 1, 2005 to December 30, 2005. The starting date to begin patient registration and qualification in iPLEDGE has been changed from November 1, 2005 to December 30, 2005. By March 1, 2006, only prescribers registered and activated in iPLEDGE will be able to prescribe isotretinoin and only patients registered and qualified in iPLEDGE will be able to be dispensed isotretinoin.
FDA ALERT [7/2005]: Suicidal Thoughts or Actions: In addition to the strengthened risk management program, FDA continues to assess reports of suicide or suicide attempts associated with the use of isotretinoin. All patients treated with isotretinoin should be observed closely for symptoms of depression or suicidal thoughts, such as sad mood, irritability, acting on dangerous impulses, anger, loss of pleasure or interest in social or sports activities, sleeping too much or too little, changes in weight or appetite, school or work performance going down, or trouble concentrating, or for mood disturbance, psychosis, or aggression. Patients should stop isotretinoin and they or their caregiver should contact their healthcare professional right away if the patient has any of the previously mentioned symptoms. Discontinuation of treatment may be insufficient and further evaluation may be necessary. [Action taken 08/12/05 Labeling revision]
This information reflects FDA’s preliminary analysis of data concerning this drug. FDA is considering, but has not reached a final conclusion about, this information. FDA intends to update this sheet when additional information or analyses become available.
iPLEDGE Update (10/6/2006): FDA is providing an update about iPLEDGE, a risk management program to reduce the risk of fetal exposure to isotretinoin (a drug to treat severe recalcitrant nodular acne). Today’s change will eliminate one element of the program, the 23 day lock-out period for males and females of non-child bearing potential (FNCBP). Previously, all patients prescribed isotretinoin had to fill their prescription within 7 days of their office visit. Patients who missed this window of opportunity and attempted to fill their prescription after 7 days had elapsed could not receive isotretinoin for another 23 days, a provision designed to prevent potential exposure to the drug during pregnancy. The elimination of the 23 day lock-out period for males and FNCBP will allow these patients the ability to have a new prescription filled immediately after the 7 day window has expired. This change does not affect female patients of child-bearing potential, and the iPLEDGE call center cannot authorize exceptions. Questions and Answers regarding iPLEDGE can be viewed at
Code:
http://www.fda.gov/cder/drug/infopage/accutane/FAQ200610.pdf.FDA ALERT [7/2005]: Suicidal Thoughts or Actions: In addition to the strengthened risk management program, FDA continues to assess reports of suicide or suicide attempts associated with the use of isotretinoin. All patients treated with isotretinoin should be observed closely for symptoms of depression or suicidal thoughts, such as sad mood, irritability, acting on dangerous impulses, anger, loss of pleasure or interest in social or sports activities, sleeping too much or too little, changes in weight or appetite, school or work performance going down, or trouble concentrating, or for mood disturbance, psychosis, or aggression. Patients should stop isotretinoin and they or their caregiver should contact their healthcare professional right away if the patient has any of the previously mentioned symptoms. Discontinuation of treatment may be insufficient and further evaluation may be necessary. [Action taken 08/12/05 Labeling revision]
This information reflects FDA’s preliminary analysis of data concerning this drug. FDA is considering, but has not reached a final conclusion about, this information. FDA intends to update this sheet when additional information or analyses become available.
Similar threads
